Details of the Drug

General Information of Drug (ID: DMXIQYS)

• Drug Name: Iodipamide
• Synonyms: Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Gallbladder disease	DC11.3	Approved	[1]

• Therapeutic Class: Contrast Media
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 1139.8
  Logarithm of the Partition Coefficient (xlogp); 5.5
  Rotatable Bond Count (rotbonds); 9
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property: Metabolism: The drug is metabolized via the hepatic []
• Chemical Identifiers:
  Formula: C20H14I6N2O6
  IUPAC Name: 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
  Canonical SMILES: C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I
  InChI: InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)
  InChIKey: FFINMCNLQNTKLU-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3739
  ChEBI ID: CHEBI:31176
  CAS Number: 606-17-7
  DrugBank ID: DB04711
  TTD ID: D07OIX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Binder	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Gallbladder disease
• ICD Disease Classification: DC11.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serum albumin (ALB)	DTT	ALB	7.92E-01	-0.07	-0.44

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Iodipamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Iodipamide caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[3]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Inotersen.	Amyloidosis [5D00]	[4]
177Lu-DOTATATE	DMT8GVU	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[4]
Givosiran	DM5PFIJ	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[4]
Moxetumomab pasudotox	DMN63DZ	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Moxetumomab pasudotox.	Mature B-cell leukaemia [2A82]	[4]
Gallium nitrate	DMF9O6B	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Gallium nitrate.	Mineral excesses [5B91]	[5]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Temsirolimus.	Renal cell carcinoma [2C90]	[5]
Telavancin	DM58VQX	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[5]
Plazomicin	DMKMBES	Major	Increased risk of nephrotoxicity by the combination of Iodipamide and Plazomicin.	Urinary tract infection [GC08]	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7400).
• [2] Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
• [3] Cerner Multum, Inc. "Australian Product Information.".
• [4] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
• [5] Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]